Earnings ·
Reports Q3 net loss of $5.6 million, updates FY26 sales guidance to approaching $900M
USNAUsana Health Sciences Inc
USANA Health Sciences reported a third-quarter net loss of $5.6 million and diluted EPS of $(0.30) for the period ended October 3, 2026. Consolidated net sales declined 4% year-over-year to $206 million, driven by lower performance in Core Nutritional and Rise Wellness, partially offset by growth at Hiya Health. The company generated $8 million in quarterly free cash flow and holds $179 million in cash with zero debt. Management updated its full-year fiscal 2026 outlook, lowering consolidated net sales guidance to approaching $900 million and Adjusted EBITDA to $77 million from previous estimates of $910 million and $80.5 million, respectively. The company operates in the health and wellness industry, developing and manufacturing nutritional supplements and functional foods sold through direct selling and retail channels.